Loading the records…
Loading the records…
The SEPSIS Act (S.1929) is an early-stage authorization bill that would create federal programs for sepsis research, education, and data collection. It authorizes but does not appropriate funding, and with only 6 cosponsors and referral to committee in June 2025, passage remains uncertain. Real market data shows all four diagnostic/lab stocks have declined 1-6% in the past week and 2-10% over 30 days, reflecting broader market pressure on healthcare despite the legislative catalyst.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The SEPSIS Act in its current form provides no material catalyst for healthcare stocks. Real market data shows BDX, TMO, DGX, LH, ABT, and GEHC are all in sharp downtrends over the past 7 and 30 days, driven by broader market factors (likely macro headwinds, sector rotation, or company-specific issues) rather than legislative sentiment. BDX at $145.31 has declined 6.16% in the past week and is 22% below its 52-week high. TMO at $466.26 has lost over $60/share since April 16. GEHC at $59.49 has dropped nearly 15% in a single week. These are not stocks showing anticipation of a sepsis-related catalyst. Investors should monitor committee activity and appropriations language in FY2027 budget cycles for potential entry points, but the current bill does not justify allocation to these names.
What happened: The SEPSIS Act (S.1929) was introduced in the Senate on June 3, 2025, by Majority Leader Schumer (D-NY) with 6 cosponsors. It was read twice and referred to the Committee on Health, Education, Labor, and Pensions. An identical companion bill (HR7116) was introduced in the House and referred to the Energy and Commerce Committee. The bill is in early legislative stages and has not progressed past committee referral in over 10 months.
The money trail: This is an authorization bill — it does not appropriate any specific dollar amount. Section 3 of the bill directs the CDC to maintain a sepsis team for education, data collection, and best practice dissemination. No funding level is specified. Actual spending would require a separate appropriations bill, which has not been introduced. The bill's findings reference the high cost of sepsis treatment ($38 billion annually per CMS data) but do not translate this into authorized spending.
Structural winners and losers: If funded, diagnostic companies would benefit from increased hospital protocol adoption. BDX ($145.31) provides blood culture and rapid diagnostic platforms used in hospitals. TMO ($466.26) supplies research equipment for sepsis biomarker discovery. DGX ($189.32) and LH ($257.14) are positioned for outpatient testing volume increases. ABT ($91.33) has sepsis-related diagnostics (Alinity i, i-STAT) but is more diversified. GEHC ($59.49) provides hospital monitoring equipment that could see demand from protocol-driven sepsis management. All remain early-stage beneficiaries contingent on future appropriations.
Real market data context: As of April 29, 2026, all relevant stocks are trading near or at their 52-week lows. BDX at $145.31 (52wk range $127.59-$187.35) is down 6.16% in the past week. TMO at $466.26 is down 0.09% weekly but sits near its 52-week low of $385.46 — a steep drop from recent close of $526.60 on April 17. DGX at $189.32 is down 5.12% weekly and approaching its 52-week low of $164.65. ABT at $91.33 is essentially at its 52-week low of $90.72 and down 10.36% over 30 days. GEHC at $59.49 has crashed 14.88% in the past week and is at its 52-week low. The broad market sell-off in healthcare names is unrelated to the SEPSIS Act, which has not progressed.
Timeline: The bill is stalled. With one action (introduction and referral) occurring 10 months ago and no hearings, markups, or floor votes, passage in the 119th Congress is unlikely unless the bill gains new sponsors or committee attention. Reintroduction in the 120th Congress (2027-2029) is possible but requires restarting the legislative process.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Authorization of federal sepsis education and data collection programs under CDC guidance may increase hospital adoption of standardized sepsis protocols, driving demand for rapid diagnostic tests and blood culture systems.
Who must act
Hospitals and healthcare facilities implementing sepsis protocols under CDC's Hospital Sepsis Program Core Elements.
What happens
Hospitals will need to procure diagnostic equipment and consumables for early sepsis detection, creating a new demand stream for blood culture and biomarker testing products.
Stock impact
BDX's diagnostic systems segment (including the BD Max and BACTEC blood culture platforms) is a primary beneficiary of expanded hospital sepsis testing protocols. Sepsis-related diagnostics represent a material growth driver within BDX's ~$5B diagnostics business.
What the bill does
Authorization of federal sepsis programs includes improving data collection and research on sepsis, which may increase demand for laboratory equipment, reagents, and clinical research tools used in sepsis biomarker discovery and validation.
Who must act
CDC, NIH, and academic research institutions conducting sepsis research under federal programs.
What happens
Increased federal funding for sepsis research will drive procurement of advanced mass spectrometry, PCR, and sequencing platforms for biomarker identification and diagnostic development.
Stock impact
TMO's life sciences solutions segment (mass spectrometers, PCR systems, reagents) is positioned to supply research tools for sepsis biomarker programs. The company's diagnostics division also benefits from any downstream test development. However, the bill authorizes but does not appropriate funds, reducing near-term revenue visibility.
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →